A Case of Intravitreal Bevacizumab Injection for the Treatment of Choroidal Neovascularization in Morning Glory Syndrome.
10.3341/jkos.2014.55.5.770
- Author:
Moon Won HWANG
1
;
Ha Na OH
;
Sung Hyup LIM
;
Hyun Woong KIM
;
Il Han YUN
Author Information
1. Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. ihyun@inje.ac.kr
- Publication Type:Case Report
- Keywords:
Choroidal neovascularization;
Intravitreal bevacizumab injection;
Morning glory syndrome
- MeSH:
Angiography;
Choroidal Neovascularization*;
Fluorescein Angiography;
Hemorrhage;
Humans;
Indocyanine Green;
Male;
Middle Aged;
Recurrence;
Retinal Detachment;
Retinoschisis;
Subretinal Fluid;
Tomography, Optical Coherence;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2014;55(5):770-774
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We report a case of intravitreal bevacizumab injection for the treatment of choroidal neovascularization in morning glory syndrome. CASE SUMMARY: A 51-year-old male visited our hospital for a 1.5-year visual disturbance in his right eye. The patient's best-corrected visual acuity was 0.1 in the right eye. After fundus examination, we found characteristic findings of morning glory syndrome with submacular hemorrhage and serous retinal detachment in the right eye. Optical coherence tomography, fluorescein angiography and indocyanine green angiography were performed for evaluation. Retinoschisis, subretinal fluid, and choroidal neovascularization were detected, and thus bevacizumab was injected in the right eye. After intravitreal bevacizumab injection, retinoschisis was improved, and subretinal fluid was decreased. However, retinal pigment epithelial detachment was newly detected, and serous retinal detachment persisted. After 2 months, a second bevacizumab injection was performed. After these intravitreal bevacizumab injections at 1 and 2 months, visual acuity was 0.4 and 0.6, respectively. Visual acuity improved to 1.0 after 3 months. Visual acuity was maintained for at least 6 months with no relapse of choroidal neovascularization. CONCLUSIONS: The choroidal neovascularization in morning glory syndrome was effectively treated with intravitreal bevacizumab injections.
